- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Wave's stock wavers on obesity drug data | ||
| Do | AI predicts liver cancer risk with "high accuracy" | ||
| Do | Corcept gets FDA OK for first-in-class ovarian cancer drug | ||
| Do | FDA clears Denali's 'game-changer' Hunter syndrome drug | ||
| Mi | Anavex sinks after pulling Alzheimer's filing in EU | ||
| Mi | ImmunityBio warned by FDA over 'misleading' Anktiva content | ||
| Mi | Grifols board backs IPO for US business | ||
| Mi | Patient sues Novartis, claiming data-tracking privacy breach | ||
| Mi | Novo unveils first data for 'triple G' agonist in diabetes | ||
| Mi | Update: Rumour confirmed as MSD buys Terns for $6.7bn | ||
| Mi | AI in drug discovery and development: news watch | ||
| Mi | MSD rumoured to be nearing $6bn play for Terns Pharma | ||
| Di | Karyopharm eyes Xpovio filing in myelofibrosis on mixed data | ||
| Di | MSD taps Quotient for IBD drug targets in $2.2bn deal | ||
| Di | AstraZeneca reportedly hit by serious cyberattack | ||
| Di | Keytruda cleared for NHS use in early head and neck cancer | ||
| Di | Gilead buys autoimmune disease biotech Ouro for $2.2bn | ||
| Mo | Sanofi pays $180m for rights to Kali autoimmune drug | ||
| Mo | Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss | ||
| Mo | FDA seeks input into 'opaque' priority voucher scheme | ||
| Mo | Dizal breaks new ground for EGFR drugs in lung cancer | ||
| Mo | Earendil raises $787m as lead TL1A antibody starts phase 2 | ||
| 20.03. | After setback, Rhythm gets good news on Imcivree from FDA | ||
| 20.03. | Novartis snaps up PI3Ka breast cancer drug in $3bn deal | ||
| 20.03. | Appeal finds NICE must reconsider Alzheimer's drugs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.